Wednesday, March 3, 2021  | 18 Rajab, 1442
Samaa TV
Facebook Twitter Youtube
HOME > Global

WHO grants ’emergency validation’ to Pfizer-BioNTech vaccine

Paves way for countries to quickly approve, import vaccine

SAMAA | - Posted: Jan 1, 2021 | Last Updated: 2 months ago
SAMAA |
Posted: Jan 1, 2021 | Last Updated: 2 months ago
WHO grants ’emergency validation’ to Pfizer-BioNTech vaccine

Photo: AFP

Listen
The World Health Organization on Thursday granted emergency validation to the Pfizer-BioNTech vaccine, paving the way for countries worldwide to quickly approve its import and distribution.  Britain launched its inoculation drive with the US-German vaccine on December 8, with the United States, Canada and EU countries following suit. WHO said the Pfizer/BioNTech vaccine was the first to receive its "emergency validation" since the novel coronavirus first broke out in China a year ago. "This is a very positive step towards ensuring global access to COVID-19 vaccines," said Mariangela Simao, a top WHO official tasked with ensuring access to medicines. "But I want to emphasise the need for an even greater global effort to achieve enough vaccine supply to meet the needs of priority populations everywhere," she said in a statement. WHO said its emergency use listing opens the way for regulators in different countries to approve the import and distribution of the vaccine. It said it also enables UNICEF, which plays a key logistical role in distributing anti-Covid vaccines, and the Pan-American Health Organization to procure the vaccine for countries that need it. WHO convened its own experts and those from around the world to review the data on the Pfizer/BioNTech vaccine’s "safety, efficacy and quality," weighing the benefits against the risks. "The review found that the vaccine met the must-have criteria for safety and efficacy set out by WHO, and that the benefits of using the vaccine to address COVID-19 offset potential risks," it said.
FaceBook WhatsApp

The World Health Organization on Thursday granted emergency validation to the Pfizer-BioNTech vaccine, paving the way for countries worldwide to quickly approve its import and distribution. 

Britain launched its inoculation drive with the US-German vaccine on December 8, with the United States, Canada and EU countries following suit.

WHO said the Pfizer/BioNTech vaccine was the first to receive its “emergency validation” since the novel coronavirus first broke out in China a year ago.

“This is a very positive step towards ensuring global access to COVID-19 vaccines,” said Mariangela Simao, a top WHO official tasked with ensuring access to medicines.

“But I want to emphasise the need for an even greater global effort to achieve enough vaccine supply to meet the needs of priority populations everywhere,” she said in a statement.

WHO said its emergency use listing opens the way for regulators in different countries to approve the import and distribution of the vaccine.

It said it also enables UNICEF, which plays a key logistical role in distributing anti-Covid vaccines, and the Pan-American Health Organization to procure the vaccine for countries that need it.

WHO convened its own experts and those from around the world to review the data on the Pfizer/BioNTech vaccine’s “safety, efficacy and quality,” weighing the benefits against the risks.

“The review found that the vaccine met the must-have criteria for safety and efficacy set out by WHO, and that the benefits of using the vaccine to address COVID-19 offset potential risks,” it said.

 
HOME  
 
 
RELATED STORIES

Tell us what you think:

Your email address will not be published.

 
 
 
 

MOST READ
MOST READ
Indian rooster kills owner with cockfight blade
Nigeria police say 317 students abducted in latest kidnapping
Three female media workers shot to death in Afghanistan
Yemen rebels claim Saudi strikes, threaten new attacks
HRW urges Iran to probe deadly shooting on Pakistan border
UK court okays extradition of Indian celebrity jeweller
 
 
 
 
 
About Us   |   Anchor Profiles   |   Online Advertising   |   Contact Us   |   Feedback   |   Apps   |   FAQs   |   Authors   |   Comment Policy
Facebook   |   Twitter   |   Instagram   |   YouTube   |   WhatsApp